Lymphoma, Leukemia & Myeloma Congress

Home
United States
New York, NY
Lymphoma, Leukemia & Myeloma Congress

The premier forum for healthcare professionals who study and manage patients with lymphoma, myeloma

For the past sixteen years, L&M has been the premier forum on the latest advances in lymphoma and myeloma. Over forty internationally-recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials. The Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphatic leukemia, lymphoma and Hodgkin’s disease.

02/15/2026

February 15 is International Childhood Cancer Day. Childhood cancers remain a leading cause of disease-related death in children worldwide. Awareness helps drive earlier diagnosis, sustained research efforts, and continued progress in outcomes.

Today is an opportunity to recognize patients, families, and care teams, and to help keep childhood cancer part of the broader oncology conversation.

02/04/2026

Change in cancer care does not happen in isolation.

World Cancer Day is a reminder that progress depends on shared effort across prevention, diagnosis, treatment, and survivorship. Advancing outcomes requires collaboration across disciplines, institutions, and communities.

Today is about recognizing that all of us working together moves the field forward.

02/01/2026

February is National Cancer Prevention Month.

This month highlights the importance of risk reduction, early detection, and clinical vigilance in reducing cancer incidence and improving outcomes. Nearly 40 percent of cancer cases are linked to modifiable risk factors.

Prevention is part of the continuum of care. Ask yourself: how can your practice reinforce prevention and early detection in the year ahead?

01/23/2026

Today we recognize Healthcare Continuing Education Professionals Day.

This is a moment to acknowledge the people behind the scenes who ensure hematology-oncology education is relevant and grounded in real clinical practice. Their work supports clinicians at every stage of learning and ultimately helps improve patient care.

Thank you for making meaningful healthcare education possible!

01/12/2026

Today is National Pharmacist Day and we want to give a big thank you to the pharmacists who support hematology care through medication management and patient education.

Your expertise strengthens care every day. We see you and honor you.

01/01/2026

Happy New Year from the LL&M family!

We’re grateful for this incredible community of clinicians, researchers, and learners—and we can’t wait to continue advancing hematologic education together in 2026.

Our first event of the new year, the LL&M Winter Symposium, kicks off at the end of January. We hope to see you there as we begin another year of progress in patient care. https://hubs.ly/Q03Y9zdp0

12/23/2025

As we reflect on another year of progress in hematologic education, we want to thank the clinicians, researchers, and partners who make this work meaningful. Wishing you a wonderful holiday season and a bright year ahead.

$The therapeutic landscape in lymphoma continues to advance, with new data informing both frontline and relapsed/refracto...$

12/20/2025

The therapeutic landscape in lymphoma continues to advance, with new data informing both frontline and relapsed/refractory management across key subtypes.

At the LL&M Winter Symposium, the sessions in “Lymphoma Landscape: Emerging Data and Clinical Impact” will deliver a focused review of the most impactful updates shaping care in 2025 and beyond.

Session Highlights:
- DLBCL in 2026: Upfront Advances and New Options for Relapsed/Refractory Disease
- Current and Emerging Management of Mantle Cell Lymphoma: Toward More Personalized Care
- Advances in Indolent Lymphomas: Follicular, Waldenström’s, and Marginal Zone Updates for 2026 Practice
- Hodgkin Lymphoma in Transition: Applying 2025 Lessons to Evolving Treatment Approaches

Join us at LL&M Winter Symposium and leave with an actionable understanding of how recent data are refining therapeutic approaches across DLBCL, MCL/MZL, WM, and HL. https://hubs.ly/Q03XT4VM0

12/19/2025

As targeted agents continue to reshape frontline CLL management, new 2025 data are refining one of the field’s most important questions: How long should patients stay on therapy?

Join Neil E. Kay, MD at the LL&M Winter Symposium for a clinically grounded look at emerging evidence—from CLL17 to next-generation combinations like sonrotoclax + obinutuzumab—and what these findings mean for real-world treatment decisions.

Don’t miss this deep dive into response-adapted strategies, MRD-driven endpoints, and the evolving role of fixed-duration therapy in frontline CLL. https://hubs.ly/Q03YbxRh0

12/17/2025

Rapid advancements in leukemia research continue to influence frontline management, induction strategies, and transplant decision-making.

At the LL&M Winter Symposium, the sessions in “Leukemia Landscape: Emerging Data and Clinical Impact” will provide an evidence-based overview of the most relevant updates shaping the leukemia care continuum heading into 2026.

Session Highlights:
- Frontline AML in 2026: Reassessing 7+3 and Advancing Targeted Triplet Induction Regimens
- MRD-Driven AML Care: Evolving Risk Assessment and Transplant Criteria for 2026
- Modernizing Myeloid Care: New Data in MDS and Emerging Evidence in Myeloproliferative Neoplasms
- Evolving Management of ALL: Applying 2025 Discoveries to 2026 Treatment Strategies

Join us in January and understand how new evidence may shift diagnostic and therapeutic approaches across the AML continuum. https://hubs.ly/Q03XS-HT0

12/12/2025

The treatment landscape for multiple myeloma continues to evolve as new data redefine frontline strategies for both transplant-eligible and transplant-ineligible patients.

At the LL&M Winter Symposium our session block “Myeloma Landscape: Emerging Data and Clinical Impact” will offer a focused, evidence-based review of the latest developments shaping clinical practice in 2026.

Session Highlights:
- Frontline Myeloma Therapy in 2026: Transplant Decisions, Bispecifics, and CAR T in Newly Diagnosed Patients
- From 2025 Discoveries to 2026 Practice: Redefining Early Relapsed Myeloma with Next-Generation Immune Therapies
- Beyond the Triple-Class Barrier: CelMoDs, Novel Agents, and Real-World Strategies for Refractory Myeloma
- Navigating High-Risk Myeloma: Smoldering Disease, Extramedullary Spread, CNS Involvement, and Plasma Cell Leukemia

Attendees will gain a clear understanding of how 2025 data may impact treatment algorithms and therapeutic sequencing in both patient groups.

Stay current on the evidence shaping next-generation myeloma care. Secure your spot today: https://hubs.ly/Q03XSW9J0

12/11/2025

Rachid Baz, MD (Moffitt Cancer Center) joins the LL&M Winter Symposium to discuss one of the fastest-moving areas in multiple myeloma:
the evolving frontline landscape for transplant-ineligible patients.

With bispecific antibodies and CAR T-cell therapy moving earlier in the disease course, Dr. Baz will break down the pivotal trials shaping what frontline care may look like in 2026 and beyond, including:

- IMMUNOPLANT – 100% MRD-negative conversion with short-course immune consolidation
- LINKER-MM4 – Early evidence for immunotherapy-only induction
- IFM2021-01 Teclille - 100% ORR and 78% VGPR in elderly patients with NDMM which compares favorably with quad therapy

Join Dr. Baz for a practical, data-driven look at how bispecifics, CAR T, and immune-based strategies could redefine treatment for TIE myeloma.

January 30 – February 1, 2026
The Ritz-Carlton, Amelia Island
Register today: https://hubs.ly/Q03XSjR30

Address

811 W 7th Avenue
New York, NY

Website

http://www.lymphomaandmyeloma.com/

Alerts

Be the first to know and let us send you an email when Lymphoma, Leukemia & Myeloma Congress posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Magnus Wellness
16 E 40th Street, Fl 4

Want your practice to be the top-listed Clinic in New York?

Our Story

For the past twenty years, L&M has been the premier forum on the latest advances in lymphoma and myeloma. Over forty internationally-recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials. The Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphatic leukemia, lymphoma and Hodgkin’s disease.